Keyword: Ian Read

Pfizer's Upjohn has reached a deal to exclusively supply generic Viagra to telehealth provider Roman as the company prepares to merge with Mylan.

With its Upjohn spinoff in the works, Pfizer could look a mess after the deal closes. But in the long run, the future is bright, one analyst said.

Ian Read is taking on an operating executive job at Carlyle, just as Robert Essner became a senior adviser at the PE firm after retiring from Wyeth.

Pfizer chairman and former CEO Ian Read has signed on as a board member for Viatris, the generics megamerger of Pfizer's Upjohn and Mylan.

Pfizer executive chairman Ian Read, who handed off the CEO baton to Albert Bourla this year, will now step aside completely and retire at year's end.

Bristol-Myers CEO Giovanni Caforio's 2018 pay package gained on revenue growth and Celgene negotiations—but took a hit from R&D results.

Vertex launched its third cystic fibrosis drug, Symdeko, and grew revenue by a hefty 40% last year—and that was enough to boost its CEO's pay by 9%.

With resolutions on the ballot at six top U.S. drugmakers, investors aim to learn how drug pricing affects executive pay.